CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of neuroblastoma
3.4.1.2. Growth in awareness & initiatives taken by the government for neuroblastoma
3.4.1.3. Rise in R&D activities
3.4.2. Restraints
3.4.2.1. Adverse effects and safety concerns
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.4.3.2. Rise in number of pipeline products
CHAPTER 4: NEUROBLASTOMA DRUGS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Immunotherapy
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Injectable
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: NEUROBLASTOMA DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Online
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Offline
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: NEUROBLASTOMA DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Type
7.2.5.1.2. Market size and forecast, by Route of Administration
7.2.5.1.3. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Type
7.2.5.2.2. Market size and forecast, by Route of Administration
7.2.5.2.3. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Type
7.2.5.3.2. Market size and forecast, by Route of Administration
7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Type
7.3.5.1.2. Market size and forecast, by Route of Administration
7.3.5.1.3. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Type
7.3.5.2.2. Market size and forecast, by Route of Administration
7.3.5.2.3. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Type
7.3.5.3.2. Market size and forecast, by Route of Administration
7.3.5.3.3. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Type
7.3.5.4.2. Market size and forecast, by Route of Administration
7.3.5.4.3. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Type
7.3.5.5.2. Market size and forecast, by Route of Administration
7.3.5.5.3. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Type
7.3.5.6.2. Market size and forecast, by Route of Administration
7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Type
7.4.5.1.2. Market size and forecast, by Route of Administration
7.4.5.1.3. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Type
7.4.5.2.2. Market size and forecast, by Route of Administration
7.4.5.2.3. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Type
7.4.5.3.2. Market size and forecast, by Route of Administration
7.4.5.3.3. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Type
7.4.5.4.2. Market size and forecast, by Route of Administration
7.4.5.4.3. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Type
7.4.5.5.2. Market size and forecast, by Route of Administration
7.4.5.5.3. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Type
7.4.5.6.2. Market size and forecast, by Route of Administration
7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Type
7.5.5.1.2. Market size and forecast, by Route of Administration
7.5.5.1.3. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Type
7.5.5.2.2. Market size and forecast, by Route of Administration
7.5.5.2.3. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Type
7.5.5.3.2. Market size and forecast, by Route of Administration
7.5.5.3.3. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Type
7.5.5.4.2. Market size and forecast, by Route of Administration
7.5.5.4.3. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Recordati Group
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. AstraZeneca plc
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Bristol-Myers Squibb Company
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Cellectar Biosciences, Inc.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.5. Eli Lilly and Company
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. MacroGenics Inc.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Pfizer Inc.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Teva Pharmaceutical Industries Ltd.
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. United Therapeutics Corporation
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Y-mabs Therapeutics, Inc.
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
| ※参考情報 神経芽腫は、小児に見られる悪性腫瘍で、主に神経系の未熟な細胞から発生します。神経芽腫は、通常、神経節や副腎にできる腫瘍であり、特に乳幼児に多く見られます。この病気は進行が早く、早期発見と適切な治療が重要です。 神経芽腫に対する治療薬はいくつかの種類に分けられ、主に化学療法、放射線療法、免疫療法、あるいは分子標的療法が使用されます。化学療法は、腫瘍細胞の増殖を抑えるために薬剤を使用する治療法です。代表的な薬剤には、シクロフォスファミド、ドキソルビシン、ビンクリスチンなどがあり、これらは一般的に多剤併用療法として使用され、腫瘍のサイズを縮小させることを目指します。 放射線療法は、高エネルギーの放射線を用いて腫瘍細胞を破壊する治療法です。特に局所的な神経芽腫に対して効果的ですが、全身に転移した場合には限界があります。放射線療法は化学療法と組み合わせて使用されることが多く、特に手術後の補助治療として用いられることが一般的です。 免疫療法は、体の免疫系を活性化させて、腫瘍細胞を攻撃させる治療法です。最近、神経芽腫に対する免疫療法の研究が進んでおり、特に単クローン抗体を利用した治療が注目されています。例えば、ディシタニブ（Unituxin）は、神経芽腫に対する特定の抗原に結合して免疫応答を誘導する薬剤です。この薬剤は、神経芽腫の再発予防に効果があるとされています。 分子標的療法は、腫瘍細胞の特定の分子を標的にすることで、その成長を抑制する治療法です。例えば、アルセントリシブ（Acilinib）は、神経芽腫に伴う特定の遺伝子変異を持つ患者に対して有効な治療法とされています。このように、神経芽腫の治療においては患者の遺伝的な背景や病状に応じて個別化されたアプローチが重要です。 最近の技術としては、遺伝子治療や細胞治療の研究が進んでいます。遺伝子治療は、腫瘍細胞の遺伝的な異常を修正することを目的としており、研究段階ではありますが、将来的には治療の一環として期待されています。また、CAR-T細胞療法は、患者自身のT細胞を遺伝子改変して腫瘍細胞を特異的に攻撃することを目指す治療法です。神経芽腫に対しても、今後の臨床試験でその有効性が検証されることが期待されます。 さらに、周囲の組織や神経系への影響を最小限に抑えるために、放射線照射の精度を向上させる技術や、画像診断技術の進歩による早期発見が重要です。MRIやPET-CTを用いた画像診断は、神経芽腫の局所的な評価や治療効果のモニタリングに役立っています。 神経芽腫の治療は、多角的なアプローチが求められる難治性の疾患です。そのため、治療薬の開発や新しい治療法の確立は、今後の医療において非常に重要なテーマとなります。また、治療の成功には、チーム医療が不可欠であり、小児科医、腫瘍医、放射線治療医、看護師、心理士など、さまざまな専門家が連携して患者をサポートすることが求められます。 これらの取り組みにより、神経芽腫の治療成績が向上し、患者のQOL（生活の質）が改善されることが期待されています。治療法の選択は、年齢や病期、病態に応じて個別に行われるべきであり、今後の研究により、新たな治療戦略が確立されることが重要です。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
